O
Ozette
Unlocking the power of the immune system to treat and prevent disease
About Ozette
Ozette is a startup that operates in the biotechnology sector, specifically focusing on the analysis of single-cell data. The company's primary goal is to enhance the understanding of the human immune system and its complexities. This is achieved through the use of artificial intelligence (AI) to analyze cellular data, which can potentially lead to the discovery of new therapies and advancements in medical treatment.
Ozette's clients are primarily research and clinical development organizations, including pharmaceutical companies and academic institutions. The company collaborates with these partners to analyze biological samples or previously generated data, aiming to provide maximum insight and value from this information.
The business model of Ozette is based on providing AI-driven computational analysis technology to its partners. This technology helps reveal distinct T cell populations that suppress immune effectiveness in the tumor microenvironment, which can inform drug development in immuno-oncology. The company generates revenue by offering these data analysis services to its partners.
In summary, Ozette is a biotech startup that uses AI to analyze single-cell data, aiming to advance medical research and therapy development. The company collaborates with research and clinical development organizations, providing them with valuable insights from their data.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Seattle, United States
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 67.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, AI Applications
- Technology
- Artificial Intelligence, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2022 | $26M | $104M | Cercano Management · M12 · OCV Partners · Alexandria Venture Investments | ↗ |
| SEED✓Equity / VC | Feb 2021 | $6M | $24M | Cercano Management · Allen Institute for AI (Ai2) · Madrona Venture Group | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ozette is 6.2K monthly website visits, up 113.8% over the last three months. Ozette's team grew 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Madrona Venture Group
Cercano Management
Allen Institute for AI (Ai2)
Series A4 investors entered at this stage
M12
OCV Partners
Alexandria Venture Investments
Duke University
Other known investors4 additional known investors
Fred Hutchinson Cancer Research Center
Allen Institute for AI Startup Incubator
Ascent Capital Advisors
Jacob Colker
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ozette on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ozette’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.